T6290

Tanespimycin (KOS 953) is an Hsp90 inhibitor (IC50=5 nM) and is selective. Tanespimycin depletes intracellular STK38/NDR1 and decreases STK38 kinase activity. Tanespimycin also downregulated stk38 gene expression.

VEGFR-2-IN-27 (compound 7a) is a potent VEGFR-2 inhibitor (IC50: 14.8 nM) suitable for anticancer research.

NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases caused by aberrant expression of IL12 and IL23.

Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential applications in cancer and infectious disease research.

PknB-IN-2 (Compound 10) is an inhibitor of Mycobacterium tuberculosis protein kinase B (PknB) with an IC50 of 12.1 μM.

GLS-1-IN-1 (compound 1d) is a GLS-1 inhibitor effective against Hep G2, MCF 7, and MCF 10A cells.

TAS-117 hydrochloride is a selective, potent, orally active allosteric Akt inhibitor, acting on Akt1 (IC50: 4.8 nM), Akt2 (IC50: 1.6 nM) and Akt3 (IC50: 44 nM). TAS-117 hydrochloride stimulates anti-myeloma activity, enhances lethal endoplasmic reticulum stress induced by proteasome inhibition, and can induce apoptosis and autophagy.

DENV-IN-6 is a potent inhibitor of DENV (I-IV), demonstrating EC50 values of 17.5, 13.20, 6.8, and 11.41 μM for the inhibition of DENV (I-IV) replication, respectively. Additionally, it exhibits anti-HIV-1 IIIB activity, with an EC50 of 0.0181 µM and a CC50 of 64.92 µM [1].

SGC agonist 2 is a potent soluble guanylate cyclase (SGC) agonist with potential therapeutic applications for cardiovascular diseases (heart failure, angina, pulmonary hypertension, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis).